The Ebola outbreak in the Democratic Republic of the Congo has become the fastest-spreading epidemic of the disease ever recorded, according to the World Health Organization. Confirmed cases reached 2,073 with 796 deaths by mid-July, crossing the 2,000-case threshold in roughly two months—a milestone that took more than ten months during the 2018–2020 outbreak in the same region. The WHO reports that over 80 percent of new infections are occurring in people not listed as known contacts, indicating that significant transmission chains remain undetected. Two-thirds of deaths are happening in communities, outside any health facility.

The current outbreak is driven by the rare Bundibugyo strain, for which no licensed vaccine or specific treatment exists. It is concentrated in Ituri province, where armed conflict, mass displacement, and deep community mistrust of medical teams are complicating containment. On 15 July, a crowd attacked Nyakunde hospital after a pregnant woman died from severe anaemia; relatives had been refused blood donation because transfusions are prohibited during Ebola outbreaks. Up to ten Ebola patients and medical staff fled the facility, and the generator powering the unit was disabled. Health workers in the region have staged protests over pay and safety, further straining the response.

Uganda, which recorded 20 confirmed cases and two deaths—mostly imported from Congo—discharged its last Ebola patient on 16 July, triggering the 42-day countdown required before the country can be declared Ebola-free. The case fatality rate of less than 10 percent is among the lowest documented in any Ebola outbreak, a result that health officials in Kampala attribute to sustained investment in preparedness, including pre-positioned supplies and trained emergency teams. Uganda has also deployed 50 health workers and four laboratories to eastern Congo to support cross-border containment. Viewed from Washington, the US has tightened entry rules: citizens returning from Congo must now spend 21 days in a third country before entering America, a measure that some aid organisations warn could deter American medical staff from volunteering in the outbreak zone.

In the race for medical countermeasures, Oxford University’s Vaccine Group has launched a Phase I clinical trial of a candidate vaccine targeting the Bundibugyo strain, with the first patient enrolled. The WHO estimates that an approved vaccine remains six to nine months away. The next factual milestones are the completion of Uganda’s 42-day countdown in late August, provided no new cases emerge, and the progression of the Oxford trial. In Congo, the US Centers for Disease Control and Prevention projects a worst-case scenario of more than 20,000 cases by mid-August, a figure that will test the international response as it contends with both a fast-moving pathogen and a volatile security environment.